ANGLE PLC (AIM:AGL, OTCQX:ANPCY) has struck a collaboration with Myriad Genetics of the US to explore whether cancer DNA captured from blood can be used alongside existing tumour tissue tests.
The liquid biopsy specialist said on Wednesday that blood samples from cancer patients would be processed using its Parsortix system, which isolates whole cancer cells circulating in the bloodstream.
These samples will then be compared against traditional tissue biopsies run through Myriad’s diagnostic assay.
The study is designed to assess whether circulating tumour cell DNA, collected from blood, provides results consistent with the DNA drawn directly from a patient’s tumour.
If successful, the approach could offer a less invasive way of gathering information to guide cancer treatment.
ANGLE CEO Andrew Newland said: "We are delighted to be working with Myriad Genetics, a major player in tissue-based companion diagnostic tests, seeking to extend their tests to work on a simple blood test using CTCs harvested by the Parsortix system.
"We look forward to working with Myriad Genetics to progress this collaboration, which has the potential to have a substantial impact on patient treatment by improving access to actionable genomic data."